{
  "meta": {
    "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.",
    "terms": "https://open.fda.gov/terms/",
    "license": "https://open.fda.gov/license/",
    "last_updated": "2026-07-08",
    "results": {
      "skip": 0,
      "limit": 1,
      "total": 1
    }
  },
  "results": [
    {
      "status": "Ongoing",
      "city": "Elmwood Park",
      "state": "NJ",
      "country": "United States",
      "classification": "Class II",
      "openfda": {},
      "product_type": "Drugs",
      "event_id": "87751",
      "recalling_firm": "QMart",
      "address_1": "495 Mola Blvd",
      "address_2": "N/A",
      "postal_code": "07407-2041",
      "voluntary_mandated": "Voluntary: Firm initiated",
      "initial_firm_notification": "Press Release",
      "distribution_pattern": "USA Nationwide",
      "recall_number": "D-0370-2021",
      "product_description": "Burro en Primavera, 2 capsules, UPC 638632431055",
      "product_quantity": "500 boxes",
      "reason_for_recall": "Marketed without Approved NDA/ANDA: FDA analysis results obtained the presence of tadalafil and/or sildenafil.",
      "recall_initiation_date": "20210331",
      "center_classification_date": "20210506",
      "report_date": "20210512",
      "code_info": "All"
    }
  ]
}